MGRX — Mangoceuticals Share Price
Last trade - 00:00- $23.20m
- $23.12m
- $0.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.16 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 26.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -62.34% | ||
| Return on Equity | -118.28% | ||
| Operating Margin | -1411.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.01 | 0.73 | 0.62 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mangoceuticals, Inc. is focused on developing men’s and women’s health and wellness products and services via a secure telemedicine platform. The Company connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. It has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 7th, 2021
- Public Since
- March 21st, 2023
- No. of Shareholders
- 40
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 11,034,023
- Address
- 15110 Dallas Pkwy, Suite 600, DALLAS, 75248
- Web
- https://www.mangorx.com/
- Phone
- Auditors
- Turner, Stone & Company
Similar to MGRX
ADVANCED BIOMED
NASDAQ Capital Market
IMEI Technology Health
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
Basel Medical
NASDAQ Capital Market
FAQ
As of Today at 21:52 UTC, shares in Mangoceuticals are trading at $1.47. This share price information is delayed by 15 minutes.
Shares in Mangoceuticals last closed at $1.47 and the price had moved by -55.47% over the past 365 days. In terms of relative price strength the Mangoceuticals share price has underperformed the S&P500 Index by -60.37% over the past year.
There is no consensus recommendation for this security.
Find out moreMangoceuticals does not currently pay a dividend.
Mangoceuticals does not currently pay a dividend.
Mangoceuticals does not currently pay a dividend.
To buy shares in Mangoceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.47, shares in Mangoceuticals had a market capitalisation of $16.22m.
Here are the trading details for Mangoceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MGRX
Based on an overall assessment of its quality, value and momentum Mangoceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mangoceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -37.06%.
As of the last closing price of $1.47, shares in Mangoceuticals were trading -53.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mangoceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Mangoceuticals' directors